All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Segmental arterial mediolysis (SAM) is a rare non-atherosclerotic, non-inflammatory vascular disorder that varies considerably in clinical course. Its\`etiology remains unclear, although some consider it a variant or a precursor of fibromuscular dysplasia (FMD) \[[@pone.0161182.ref001], [@pone.0161182.ref002]\]. Others have suggested that SAM is a secondary phenomenon, resulting from vasospasm or arterial wall injury due to immune complexes \[[@pone.0161182.ref003]\]. Originally described in 1976 by Slavin et al \[[@pone.0161182.ref004]\], only around 100 cases of SAM have since been reported in the literature \[[@pone.0161182.ref005]\].

SAM is typically manifested in splanchnic arteries where lytic degeneration of medial smooth muscle occurs, culminating in tearing/separation from adventitia and adjacent fibrosis. Patients variably present with dissection, aneurysm, stenosis, occlusion, or hemorrhage after rupture, often calling for emergency surgical or endovascular intervention. Unfortunately, no standard criteria exist at present for differentiating SAM from inflammatory vasculitis, and the clinical course of SAM is varie, with no clear tendency to progress, resolve, or stabilize. Likewise, there are no established therapeutic or monitoring guidelines stipulating circumstances where surgical or other interventions are indicated.

The purpose of this study is to review our experience with SAM management and to suggest an optimal management and surveillance strategy in SAM through thorough literature review.

Methods {#sec006}
=======

A retrospective review of eight consecutive patients (male, 4; female, 4) diagnosed with SAM between January, 2000 and January, 2012 was conducted with approval of the Institutional Review Board (IRB No SNUH-1408-027-601). The obtainment of informed consent was waived and patient information/records were anonymized and de-identified prior to analysis.

Diagnosis of SAM {#sec007}
----------------

Diagnostic criteria developed by Kalva et al \[[@pone.0161182.ref006]\] were applied, relying upon presenting clinical features, imaging studies, and laboratory findings. Briefly, patients experiencing acute or chronic abdominal pain, flank pain, or no symptoms qualified as SAM, in the absence of any congenital predisposition for dissection (eg, Ehlers-Danlos, Marfan's, or Loeys-Dietz syndrome) and after excluding more common alternatives, namely FMD, collagen vascular disorders, or arteritis. On imaging studies, dissection, aneurysm, or occlusion involving multiple splanchnic arteries was characteristically found findings. No inflammatory markers of vasculitis (ie, ANCA, C3/C4, FANA, RF, anti-La antibodies, and anti-cardiolipin antibodies) were elevated on laboratory testing.

Treatment and Surveillance of SAM {#sec008}
---------------------------------

Treatment of SAM generally was conservative, including strict control of blood pressure, resting of the bowel (if mesenteric arteries involved), and close observation, prohibiting use of anticoagulants or antiplatelet agents. CT angiographic studies were repeated at Week 1 and at Month 3 after diagnosis and thereafter were done yearly. On occasion, CT angiography was ordered more often (at physician's discretion) if new lesions or symptoms developed. In patients requiring superior mesenteric arterial stenting, self-expandable stents were placed in a manner reported previously \[[@pone.0161182.ref007]\].

Literature review {#sec009}
-----------------

PubMed databases were searched for all articles published in English between January 1, 1976 and August 31, 2015. "Segmental arterial mediolysis" and "segmental mediolytic arteritis" served as keyword combinations. All abstracts, case reports, patient series and citations scanned were examined. Extraction of study data was achived using a standardized template, which included author\`s name, publication year, patient demographics, affected arteries, clinical presentations, and treatment methods. A full description of search terms, strategy and screening stages are provided in [S1 Table](#pone.0161182.s003){ref-type="supplementary-material"}.

This literature review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([S1 PRISMA Checklist](#pone.0161182.s001){ref-type="supplementary-material"}, [S1 PRISMA Flow Diagram](#pone.0161182.s002){ref-type="supplementary-material"}).

Statistical analysis {#sec010}
--------------------

We analyzed variables of our case series and of those in the literature. Because events were relatively few and biased, the binomial Clopper Pearson exact method was used to generate 95% confidence intervals.

Results {#sec011}
=======

Patients demographics {#sec012}
---------------------

From January 1, 2000 to January 31, 2012, a total of 8 patients were diagnosed as SAM ([Table 1](#pone.0161182.t001){ref-type="table"}). Median age was 62.8 years (range, 40--84 years, 95% CI range, 51.7--73.8 years), and median follow-up period was 26 months (range, 15--57 months). All patients presented with acute abdominal or flank pain. Relevant patient comorbidities included hypertension (25%), atrial fibrillation (25%), congestive heart failure (12.5%), and hyperlipidemia (25%). Only one patient was a current smoker (20 pack-years), the rest denying such habit. None of the patients had family histories or clinical manifestations suggesting congenital predispositions for dissection (eg, Marfan's syndrome, Ehlers-Danlos syndrome, and FMD).

10.1371/journal.pone.0161182.t001

###### Baseline demographic and clinical characteristics of patients.

![](pone.0161182.t001){#pone.0161182.t001g}

  Variables                                        Patients (N = 8)   95% CI
  ------------------------------------------------ ------------------ -------------------
  Age: median (range), y                           62.8 (40--84)      62.8 (51.7--73.8)
  Gender (male:female)                             4:4                50.0 (15.7--84.3)
  Initial presentation as abdominal pain, n (%)    7 (87.5%)          87.5 (47.4--99.7)
  Initial presentation as flank pain, n(%)         1 (12.5%)          12.5 (0.3--52.7)
  Comorbidities, hypertension, n (%)               2 (25%)            25 (3.2--65.1)
  Comorbidities, congestive heart failure, n (%)   1 (12.5%)          12.5 (0.3--52.7)
  Comorbidities, hyperlipidemia, n (%)             2 (25%)            25 (3.2--65.1)
  Comorbidities, smoking, n (%)                    1 (12.5%)          12.5 (0.3--52.7)
  Family history of arterial disease               0 (0%)             0 (0--36.9)
  Histologic diagnosis                             0 (0%)             0 (0--36.9)

Detailed clinical and imaging findings at presentation and during follow-up of patients are summarized in [Table 2](#pone.0161182.t002){ref-type="table"}.

10.1371/journal.pone.0161182.t002

###### Clinical and imaging findings at presentation and follow-up.

![](pone.0161182.t002){#pone.0161182.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.      Age (y) /Gender   Clinical presentation   Follow up (months)   Comorbidity                  Initial CT angiography                                                         Newly developed arterial lesion at follow-up CT angiography   Endovascular treatment
  -------- ----------------- ----------------------- -------------------- ---------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------
  1        63/M              Abdominal pain          17                   None                         SMA dissection                                                                 • Progression of SMA dissection\                              SMA stent insertion
                                                                                                                                                                                      • SMA branch aneurysm\                                        
                                                                                                                                                                                      • Marginal artery occlusion(2 months later)                   

  2        56/M              Abdominal pain          25                   HTN, Hyperlipidemia, A.fib   SMA dissection                                                                 • Right renal artery dissection\                              \-
                                                                                                                                                                                      • Left renal artery dissection with ectasia (1 week later)    

  3        70/F              Abdominal pain          15                   Hyperlipidemia               Celiac axis and CHA dissection                                                 Stable                                                        \-

  4        84/F              Abdominal pain          19                   HTN,                         Aneurysm of PHA, RHA, LHA, LGA, and RGEA right renal artery stenosis           Stable                                                        Right renal artery stent insertion

  A.fib,                                                                                                                                                                                                                                            

  CHF,                                                                                                                                                                                                                                              

  5        66/M              Abdominal pain          57                   None                         SMA dissection                                                                 • Progression of SMA dissection\                              SMA Stent insertion
                                                                                                                                                                                      • Pancreaticoduodenal artery aneurysm (9 days later)          

  6        70/F              Abdominal pain          38                   None                         SMA dissection, Right colic artery dissection, Middle colic artery occlusion   Ileocolic artery aneurysm (1 month later)                     \-

  7        40/M              Lt. flank pain          15                   None                         Celia axis stenosis, CHA stenosis, Splenic artery occlusion                    Stable                                                        \-

  8        53/F              Abdominal pain          22                   None                         GDA pseudoaneurysm, Celiac axis dissection                                     Stable                                                        Embolization
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*No*., number; *CT*, computed tomography; *SMA*, Superior mesenteric artery; *CHA*, common hepatic artery; *PHA*, proper hepatic artery; *RHA*, right hepatic artery; *LHA*, left hepatic artery; *LGA*, left gastric artery; *RGEA*, right gastroepiploic artery; *GDA*, gastroduodenal artery; HTN, hypertension; A.fib, atrial fibrillation; CHF, congestive heart failure.

Markers of inflammatory vascular disease, such as anti-neutrophil cytoplasmic antibody (ANCA), complement C3/C4, fluorescent antinuclear antibody (FANA), rheumatoid factor (RF), anti-La antibodies, and anti-cardiolipin antibodies, were all negative. C-reactive protein was elevated in one patient showing a splenic infarct (patient No.7).

Arterial involvement of SAM {#sec013}
---------------------------

All eight patients were subjected to CT angiography at presentation, identifying 19 lesions as follows: celiac axis, three (37.5%); superior mesenteric artery (SMA), four (50%); common hepatic artery, two (25%); and one each involving right renal, splenic, right colic, middle colic, gastroduodenal, left gastric, right gastroepiploic, proper hepatic, right hepatic, and left hepatic arteries. A number of dissections (n = 8), aneurysms (n = 5), and stenoses or occlusions (n = 5), as well as a single pseudoaneurysm were demonstrated ([Table 2](#pone.0161182.t002){ref-type="table"}).

During follow-up, all patients underwent CT angiography periodically in accord with study protocol. Upon conclusion, 25 lesions ultimately accrued, including three additional aneurysms (SMA branch, pancreaticoduodenal and ilieocolic arteries), marginal artery occlusion, and bilateral renal arterial dissections ([Table 2](#pone.0161182.t002){ref-type="table"}).

Surveillance results {#sec014}
--------------------

Although patient No. 8 underwent endovascular embolization of an initially identified gastroduodenal pseudoaneurysm ([Fig 1](#pone.0161182.g001){ref-type="fig"}), other patients opted for regular monitoring. At completion of the follow-up period, lesions in four patients were stable, whereas new arterial lesions developed in the other four (No. 1, 2, 5, 6). In one patient (No. 1), a SMA branch aneurysm and a marginal arterial occlusion appeared at Month 2. Another patient (No. 2), presenting with SMA dissection, displayed dissections of right and left renal arteries with ectasia at Week 1 ([Fig 2](#pone.0161182.g002){ref-type="fig"}). Patient No. 5, also presented with SMA dissection and developed a pancreaticoduodenal aneurysm by Day 9. Finally, patient No. 6 developed an ileocolic aneurysm at Month 1 ([Fig 3](#pone.0161182.g003){ref-type="fig"}).

![**Initial CT scans (patient No. 8):** (**A**) celiac axis arterial dissection and (**B**) pseudoaneurysm of gastroduodenal artery.](pone.0161182.g001){#pone.0161182.g001}

![**CT angiography (patient No. 2):** (**A & B**) SMA dissection seen initially, with normal renal vasculature interpreted as symptomatic isolated dissection of superior mesenteric artery until follow-up imaging (1 week later) confirmed (**C**) new dissections of right and left right renal arteries with ectasia.](pone.0161182.g002){#pone.0161182.g002}

![**CT angiography (patient No. 6):** (**A**) SMA dissection at presentation (in addition to right colic arterial dissection and occlusion of middle colic artery); (**B**) newly developed aneurysm of ileocolic artery seen 1 month after initial visit.](pone.0161182.g003){#pone.0161182.g003}

Among these patients, symptomatic isolated dissection of SMA (SIDSMA) was first considered in three (No. 1, 2, 5). However, a diagnosis of SAM was made after other splanchnic arterial lesions materialized. Two patients (No. 1, 5) required stent placement due to progression of dissection, as specified in our previously published recommendations \[[@pone.0161182.ref007]\].

Literature cases {#sec015}
----------------

To date there are 76 studies and 101 cases of SAM (Tables [3](#pone.0161182.t003){ref-type="table"} and [4](#pone.0161182.t004){ref-type="table"}), of which 60 were men and 41 were women. Median age was 56.9 years (range, 0--91 years 95% CI range,). Most patients presented with abdominal pain (68%), whereas eight patients were asymptomatic. In 68 patients (67%), diagnosis was confirmed by histologic means. Others were diagnosed clinically. The vessel most often associated with SAM was splenic artery, accounting for 28% of all SAM involvement. Common hepatic artery (and hepatic branches), celiac trunk, and renal arteries were the next most commonly involved.

10.1371/journal.pone.0161182.t003

###### Baseline demographic and clinical characteristics of literature cases.

![](pone.0161182.t003){#pone.0161182.t003g}

  Variables                                             Patients (n = 101)   95% CI
  ----------------------------------------------------- -------------------- -------------------
  Age: median (range), y                                56.9 (0--91)         56.9 (53.8--60.0)
  Gender (male:female)                                  60:41                59.4 (49.2--69.1)
  Initial presentation as abdominal pain                69 (68%)             68.3 (58.3--77.2)
  Histologic diagnosis                                  68 (67%)             67.3 (57.3--76.3)
  Management                                                                 
  Conservative management                               14 (14%)             13.9 (7.8--22.2)
  Endovascular intervention                             24 (24%)             23.8 (15.9--33.3)
  Open surgery after failed endovascular intervention   7 (7%)               6.9 (2.8--13.8)
  Open surgery                                          41 (41%)             40.6 (30.9--50.8)
  None mentioned or attempted                           15 (15%)             14.9 (8.6--23.3)

10.1371/journal.pone.0161182.t004

###### Included studies and outcomes of interest.

![](pone.0161182.t004){#pone.0161182.t004g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                         Year   No. of cases   Histologic confirmation   Management               Outcome   SAM involved vessels
  --------------------------------------------------------------- ------ -------------- ------------------------- ------------------------ --------- ----------------------------------------------------------------------------------
  Matsuda et al.\[[@pone.0161182.ref008]\]                        2015   1              Yes                       O after failed EV        S         Splenic a.

  Kimura et al.\[[@pone.0161182.ref009]\]                         2015   1              Yes                       O after failed EV        S         Inf. PDA

  Liao et al.\[[@pone.0161182.ref010]\]                           2015   1              No                        EV                       S         SMA

  Ruderman et al.\[[@pone.0161182.ref011]\]                       2015   1              No                        EV                       S         Renal a.

  Nishimura et al.\[[@pone.0161182.ref012]\]                      2014   1              No                        O                        S         Middle colic a.

  Galketiya et al.\[[@pone.0161182.ref013]\]                      2014   1              Yes                       O                        S         Lt. colic a.

  Horsley et al.\[[@pone.0161182.ref014]\]                        2014   1              No                        C                        S         SMA, IMA, ileocolic a. Hepatic a.

  Yamamoto et al.\[[@pone.0161182.ref015]\]                       2014   1              No                        EV                       S         PDA

  Marshall et al.\[[@pone.0161182.ref016]\]                       2013   2              1\. Yes\                  1\. O after failed EV\   1\. S\    1\. Hepatic a.\
                                                                                        2. Yes                    2. O after failed EV     2. S      2. Hepatic a.

  Kidogawa et al.\[[@pone.0161182.ref017]\]                       2013   1              No                        C                        S         Inf. PDA

  Alturkustani et al.\[[@pone.0161182.ref018]\]                   2013   2              1\. Yes\                  1\. N\                   1\. DS\   1\. VA\
                                                                                        2. Yes                    2. N                     2. DS     2. VA

  Tabassum et al.\[[@pone.0161182.ref019]\]                       2013   1              Yes                       O                        S         LGA

  Yoshida et al.\[[@pone.0161182.ref020]\]                        2013   1              Yes                       O                        S         Lt. colic a.

  Ushijima et al.\[[@pone.0161182.ref021]\]                       2013   1              No                        O                        S         Post. inf. PDA

  Yoo et al.\[[@pone.0161182.ref022]\]                            2012   1              No                        EV                       S         SMA, middle colic a.

  Matsuda et al.\[[@pone.0161182.ref023]\]                        2012   1              No                        O                        S         Ant. cerebral a., Lt. VA

  Ito et al.\[[@pone.0161182.ref024]\]                            2012   1              No                        C                        S         SMA, IMA, Lt. renal a. Splenic a.

  Hatogai et al.\[[@pone.0161182.ref025]\]                        2012   1              Yes                       O                        S         Hepatic a., Celiac artery

  Cooke et al.\[[@pone.0161182.ref026]\]                          2012   1              No                        EV                       S         VA

  Filippone et al.\[[@pone.0161182.ref027]\]                      2011   2              1\. No\                   1\. C\                   1\. S\    1\. Rt. renal a., Rt. carotid a., Both VA, Lt. middle cerebral a. Both renal a.\
                                                                                        2. Yes                    2. O                     2. S      2. Hepatic a., SMA

  Gahide et al.\[[@pone.0161182.ref028]\]                         2011   1              No                        EV                       S         Lt. renal a.

  Obara et al.\[[@pone.0161182.ref029]\]                          2011   1              No                        EV                       S         Splenic artery, Celiac artery

  Oki et al.\[[@pone.0161182.ref030]\]                            2011   1              Yes                       O                        S         Rt. renal a.

  Tomonaga et al.\[[@pone.0161182.ref031]\]                       2011   1              No                        C                        S         Hepatic a.

  Tameo et al.\[[@pone.0161182.ref032]\]                          2011   1              Yes                       O after failed EV        S         SMA

  Fujiwara et al.\[[@pone.0161182.ref033]\]                       2011   1              Yes                       O after failed EV        S         Middle colic a.

  Naitoh et al.\[[@pone.0161182.ref034]\]                         2010   1              No                        EV                       S         Splenic a. Celiac a.

  Baker-LePain et al.\[[@pone.0161182.ref035]\]                   2010   2              1\. Yes\                  1\. O\                   1\. S\    1\. Hepatic a., Lt. colic a., Splenic a.\
                                                                                        2. Yes                    2. O                     2. S      2. Celiac a., Splenic a. Hepatic a.

  Davran et al.\[[@pone.0161182.ref036]\]                         2010   3              1\. No\                   1\. EV\                  1\. S\    1\. Rt. renal a., SMA, Celiac a.\
                                                                                        2. No\                    2. EV\                   2. S\     2. Hepatic a., Renal a., SMA\
                                                                                        3. No                     3. EV                    3. S      3. SMA, PDA

  Soga et al.\[[@pone.0161182.ref037]\]                           2009   1              Yes                       C                        DN        Renal a.

  Ro et al.\[[@pone.0161182.ref038]\]                             2009   1              Yes                       N                        DS        RGEA, LGA, VA

  Keuleers et al.\[[@pone.0161182.ref039]\]                       2009   1              Yes                       O                        S         Ascending aorta

  Kahn et al.\[[@pone.0161182.ref040], [@pone.0161182.ref041]\]   2009   1              Yes                       O                        DS        Splenic a., Celiac a., Middle colic a.

  Agarwal et al.\[[@pone.0161182.ref042]\]                        2009   2              1\. No\                   1\. C\                   1\. S\    1\. Splenic a., Celiac a.\
                                                                                        2. No                     2. EV                    2. S      2. SMA, Renal a., Celiac a., Splenic a., GEA

  Hirokawa et al.\[[@pone.0161182.ref043]\]                       2009   1              No                        EV                       S         Middle colic a.

  Ro et al.\[[@pone.0161182.ref044]\]                             2008   1              Yes                       N                        DS        Vertebral a., Basilar a., Internal carotid a.

  Hashimoto et al.\[[@pone.0161182.ref045]\]                      2008   1              Yes                       EV (then elective O)     S         Splenic a., GEA, SMA

  Abdelrazeq et al.\[[@pone.0161182.ref046]\]                     2008   1              Yes                       O after failed EV        S         Marginal a. of Drummond

  Shimohira et al.\[[@pone.0161182.ref047]\]                      2008   4              1\. No\                   1\. EV\                  1\. S\    1\. Hepatic a., Splenic a.\
                                                                                        2. No\                    2. EV\                   2. S\     2. GEA\
                                                                                        3. No\                    3. EV\                   3. S\     3. Middle colic a., Hepatic a., Celiac a.\
                                                                                        4. No                     4. EV                    4. S      4. IMA, Lt. colic a.

  Mizutani et al.\[[@pone.0161182.ref048]\]                       2008   1              No                        EV                       S         Rt. renal a.

  Takahashi et al.\[[@pone.0161182.ref049]\]                      2007   1              No                        EV                       S         Middle colic a.

  Muller and Kullmann\[[@pone.0161182.ref050]\]                   2006   1              Yes                       O                        S         Pulmonary arterioles

  Rosenfelder et al.\[[@pone.0161182.ref051]\]                    2006   1              Yes                       O                        S         Colic a., Mid-jejunal a., Hepatic a., GA

  Michael et al.\[[@pone.0161182.ref052]\]                        2006   5              1\. No\                   1\. C\                   1\. S\    1\. Celiac a., SMA, Hepatic a.\
                                                                                        2. No\                    2. EV\                   2. S\     2. Celiac a., Hepatic a., GDA, Lt. renal a.\
                                                                                        3. Yes\                   3. O\                    3. S\     3. SMA, GDA, Middle colic a.\
                                                                                        4. Yes\                   4. N\                    4. DS\    4. Middle colic a.\
                                                                                        5. No                     5. C                     5. S      5. SMA, Renal a., Jejunal a.

  Phillips and Lepor\[[@pone.0161182.ref053]\]                    2006   1              Yes                       O                        S         Lt. renal a.

  Obara et al.\[[@pone.0161182.ref054]\]                          2006   1              Yes                       O                        S         Lt. ICA, Celiac a., SMA, Hepatic a.

  Imai et al.\[[@pone.0161182.ref055]\]                           2005   1              Yes                       N                        DS        Splenic a.

  Yamakawa et al.\[[@pone.0161182.ref056]\]                       2005   2              1\. Yes\                  1\. O\                   1\. S\    1\. Post. inf. cerebellar a.\
                                                                                        2. Yes                    2. O                     2. DS     2. Post. inf. cerebellar a.

  Jibiki et al.\[[@pone.0161182.ref057]\]                         2005   1              Yes                       O                        S         PDA, Celiac a., Splenic a.

  Basso et al.\[[@pone.0161182.ref058]\]                          2005   2              1\. Yes\                  1\. O\                   1\. DS\   1\. Submucosal and serosal intestinal a.\
                                                                                        2. Yes                    2. C                     2. DS     2. Both ICA

  Hirakawa et al.\[[@pone.0161182.ref059]\]                       2005   4              1\. Yes\                  1\. O\                   1\. U\    1\. Celiac a., LGA, Splenic a., CHA\
                                                                                        2. Yes\                   2. O\                    2. U\     2. Celiac a., LGA, Splenic a.\
                                                                                        3. Yes\                   3. O\                    3. U\     3. Celiac a., LGA\
                                                                                        4. Yes                    4. O                     4. U      4. Splenic a.

  Chino et al.\[[@pone.0161182.ref060]\]                          2004   1              Yes                       O                        S         Middle colic a.

  Nishiyama et al.\[[@pone.0161182.ref061]\]                      2004   1              Yes                       N                        DS        LGA

  Soulen et al.\[[@pone.0161182.ref062]\]                         2004   1              No                        EV                       S         CHA, Splenic a., Both renal a., GDA, SMA

  Rengstorff et al.\[[@pone.0161182.ref063]\]                     2004   1              Yes                       O                        S         IMA

  Yamada et al.\[[@pone.0161182.ref064]\]                         2004   1              Yes                       O                        S         Lt. common iliac a.

  Eifinger et al.\[[@pone.0161182.ref065]\]                       2004   1              Yes                       C                        DS        Placental a., Umbilical cord a.

  Takagi et al.\[[@pone.0161182.ref066]\]                         2003   1              Yes                       O                        S         Celiac a., Splenic a., Lt. renal a.

  Ohta et al.\[[@pone.0161182.ref067]\]                           2003   1              Yes                       EV (then elective O)     S         Vertebro-basilar junction, Ant. Communicating a., Lt. superficial temporal a.

  Sakata et al.\[[@pone.0161182.ref068]\]                         2002   1              Yes                       C                        DS        Rt.VA, Lt. ICA, SMA, Bilateral renal a., Lt. EIA

  Ryan et al.\[[@pone.0161182.ref069]\]                           2000   1              No                        EV                       S         Hepatic a.

  Chan et al.\[[@pone.0161182.ref070]\]                           1998   1              Yes                       O                        S         Hepatic a., Splenic a.

  Nagashima et al.\[[@pone.0161182.ref071]\]                      1998   1              Yes                       N                        DS        PHA

  Sakano et al.\[[@pone.0161182.ref072]\]                         1997   1              Yes                       O                        S         Middle colic a.

  Kato et al.\[[@pone.0161182.ref073]\]                           1996   1              Yes                       O                        S         IMA

  Peters et al.\[[@pone.0161182.ref074]\]                         1995   1              Yes                       C                        DS        ICA

  Ito et al.\[[@pone.0161182.ref075]\]                            1995   1              Yes                       C                        DS        Splenic a.

  Slavin et al.\[[@pone.0161182.ref001]\]                         1995   5              1\. Yes\                  1\. O\                   1\. S\    1\. Lt. colic a.\
                                                                                        2. Yes\                   2. N\                    2. DN\    2. Epicardial coronary a.\
                                                                                        3. Yes\                   3. O\                    3. S\     3. Ileocolic a.\
                                                                                        4. Yes\                   4. N\                    4. DN\    4. Hepatic a.\
                                                                                        5. Yes                    5. N                     5. DS     5. GEA

  Wang and Huang\[[@pone.0161182.ref076]\]                        1994   1              Yes                       O                        S         Lt. colic a.

  Juvonen et al.\[[@pone.0161182.ref077]\]                        1994   1              Yes,                      O                        S         Omental a., Splenic a., Pancreatic a.

  Eskenasy-Cottier et al.\[[@pone.0161182.ref078]\]               1994   1              Yes                       N                        DS        Ant. Circulation of the circle of Willis

  Inayama et al.\[[@pone.0161182.ref079]\]                        1992   1              Yes                       O                        S         LGA, Splenic a.

  Armas and Donovan\[[@pone.0161182.ref080]\]                     1992   1              Yes                       N                        DS        Hepatic a.

  Heritz et al.\[[@pone.0161182.ref081]\]                         1990   1              Yes                       O                        S         Omental a., Ileal a., GDA, Renal a.

  Slavin et al.\[[@pone.0161182.ref082]\]                         1989   1              Yes                       O                        S         Jejunal a.

  Slavin et al.\[[@pone.0161182.ref004]\]                         1976   3              1\. Yes\                  1\. N\                   1\. DS\   1\. Splenic a.\
                                                                                        2. Yes\                   2. N\                    2. DS\    2. Rt. colic a.\
                                                                                        3. Yes                    3. N                     3. DS     3. Lt. colic a.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*C*, Conservative management; *DN*, died from causes not directly related to segmental arterial mediolysis; *DS*, died as a direct consequence of segmental arterial mediolysis or segmental arterial mediolysis-related sequelae; *EV*, endovascular intervention; *N*, none mentioned or attempted; *O*, open surgery; *S*, survived; *U*, outcome not reported; *No*., number; *SMA*, Superior mesenteric artery; *CHA*, common hepatic artery; *PHA*, proper hepatic artery; *RHA*, right hepatic artery; *LHA*, left hepatic artery; *LGA*, left gastric artery; *RGEA*, right gastroepiploic artery; *GEA*, gastroepiploic artery; *GDA*, gastroduodenal artery; *PDA*, pancreaticoduodenal artery; *GA*, gastric artery; *ICA*, internal carotid artery; *VA*, vertebral artery; *EIA*, external iliac artery.

Of the 94 cases with reported survival outcomes, SAM-related mortality was 22% (21 patients), with 78% (73 patients) surviving acute presentations of SAM. Of the 21 patients who died of SAM-related causes, 13 reportedly died before any intervention could be attempted (i.e., death on arrival to hospital) or without intervention, and five died despite attempts at nonoperative conservative management.

Eventually only 14 patients were conservatively managed. Another 47 patients underwent surgical ligation of bleeding vessels/or resection of aneurysmal segment, often with vascular reconstruction either as primary management or after failed endovascular intervention. Twenty-four patients were managed by endovascular intervention through sole use of coil embolization.

In most cases reviewed, follow-up indicated that patients were largely asymptomatic clinically, with additional imaging showing variable outcomes from complete resolution to no change in untreated aneurysm \[[@pone.0161182.ref005]\]. Few reports of new arterial lesions appears in the literature.

Discussion {#sec016}
==========

Slavin et al (1976) were the first to define SAM, describing this pathologically distinct entity based on three autopsies. Fundamentally, SAM involves lytic degeneration of medial smooth muscle leading to tearing/separation from adventitia and adjacent fibrosis. Hence, patients commonly present with aneurysms, dissections, stenoses and ruptures, often requiring emergency surgical or endovascular intervention \[[@pone.0161182.ref032]\].

The 101 cases of SAM that have been reported thus far likely represent a gross underestimate of its true incidence. Typically, splanchnic vessels of middle-aged and elderly adults are affected in SAM, although carotid, renal, intracranial, and iliac arterial involvement has been reported, and some cases have developed in young individuals. To date, some authorities insist that SAM represents a variant or a precursor of FMD \[[@pone.0161182.ref001], [@pone.0161182.ref002]\]. However, young females are usually afflicted with FMD, showing diffuse disarray of media in mid- and distal arterial segments where smooth muscle is replaced by collagen \[[@pone.0161182.ref006], [@pone.0161182.ref083]\]. Arterial stenoses are common in FMD, but aneurysms and dissections are rare \[[@pone.0161182.ref035], [@pone.0161182.ref083]\]. The differential diagnosis also includes Marfan's syndrome, polyarteritis nodosa, Takayasu's arteritis, Behçet's disease, allergic granulomatous angiitis, and various disorders of collagen (eg, Ehlers-Danlos syndrome, Loeys-Dietz syndrome, and neurofibromatosis) \[[@pone.0161182.ref035]\]. SAM differs significantly in terms of pathologic findings, laboratory abnormalities, and sites of involvement, predominantly involving splanchnic vasculature and presenting distinctively. Marfan's and Ehlers-Danlos syndromes commonly manifest as dissections and aneurysms. Loeys-Dietz syndrome also is usually marked by aneurysms. Although neurofibromatosis may produce long-segment stenosis and aneurysms, dissections are rare \[[@pone.0161182.ref035]\].

In a literature review, abdominal pain was the most common presenting symptom (68%), followed by hemodynamic shock (25%), neurologic symptom (12%), and 11 patients (11%) died before further investigation and/or attempted management. However, eight cases (8%) reported an asymptomatic presentation. In our review, seven of our patients (87.5%) presented with acute abdominal pain and one patient experienced acute flank pain.

Mean age at presentation was slightly higher in our patients, compared with the pooled data of literature review (62.8 vs 56.9 years). Multiple vessels were initially involved in five of our patients (62.5%), as opposed to 47% in other reports \[[@pone.0161182.ref054], [@pone.0161182.ref084]\]. Some sources further suggest that multiple splanchnic vessels are affected during the course of SAM \[[@pone.0161182.ref032]\]. In support of this tenet, half of our patients developed new lesions of splanchnic arteries (Pt. No. 1, 2, 5, 6) ([Table 1](#pone.0161182.t001){ref-type="table"}). Consequently, careful clinical follow-up is recommended, checking regularly for new arterial lesions via CT angiography. According to our protocol, CT angiography is done at presentation and repeated periodically (Week 1 and Month 3 after diagnosis, then yearly). Only if initial lesions resolve completely within the first year of follow-up is yearly imaging abandoned. In reviewing the literature, only in a few instances did new lesions develop during the course of SAM. A high index of suspicion and careful evaluation of imaging studies are essential in this regard. Our imaging protocol during follow-up periods may certainly played a role here.

Three of our patients (37.5%) were initially considered as SIDSMA in our series. Once new splanchnic arterial lesions materialized, a diagnosis of SAM was eventually established. It may well be that SIDSMA is a preliminary manifestation of SAM. Regular imaging and careful monitoring are thus prudent in instances of SIDSMA as well.

No formal guidelines for management of SAM exist as yet. Patients with shock and intra-abdominal hemorrhage should be treated with emergency surgical or endovascular intervention. If a lesion progresses, increasing the risk of organ ischemia, endovascular intervention is perhaps the foremost therapeutic option \[[@pone.0161182.ref032]\]. Previous studies have indicated that a benign course of the disease requires no therapy \[[@pone.0161182.ref052]\]. Given that the arterial walls are already prone to dissection or development of aneurysms, intra-arterial catheter manipulation and balloon dilatation stand to worsen or instigate arterial dissections. Accordingly, invasive procedures may be reserved for patients with hemodynamically unstable conditions or significant end-organ ischemia \[[@pone.0161182.ref047], [@pone.0161182.ref063], [@pone.0161182.ref069], [@pone.0161182.ref085]\]. Four of our patients submitted to endovascular interventions. Two had stents placed in SMA, adhering to related treatment guidelines of our group; \[[@pone.0161182.ref007]\] one underwent coil embolization for a pseudoaneurysm of gastroduodenal artery with bleeding; and in another we opted for right renal arterial stent insertion due to progressing azotemia. No surgical interventions were done. The utility of corticosteroids in the management of this disease is questionable, given the absence of inflammation in histologic preparations. Active management of hypertension may otherwise be beneficial \[[@pone.0161182.ref062]\].

The present study has several limitations. As other case series reports, our initiative deals with a small group of patients (N = 8). The latter may seem abundant by comparison, relative to 101 similar case reports in the literature, but small patient samplings provide only limited perspective of this disease entity. In addition, none of the arterial lesions had pathologic confirmation, which would have been prohibitive. Each diagnosis was based solely on clinical and imaging findings, in conjunction with an absence of laboratory abnormalities and exclusion of diagnostic alternatives \[[@pone.0161182.ref006]\]. We applied diagnostic criteria of Kalva et al for this study. Nevertheless, these criteria are in need of further validation. The present study was also retrospective in nature, relying upon only eight patients. However, in the only prior study of more than eight patients, CT angiographic data were insufficient. By comparison, our efforts have generated a significant body of information on SAM, addressing diagnosis, therapy, and follow-up management. With increasing awareness of SAM, new studies are coming forward. The clear potential for misdiagnosis means that untold sufferers fail to receive proper treatment or due vigilance. A multicenter observation registry may offer better insights into clinical and imaging characteristics of SAM, accruing sufficient case numbers for prospective investigation.
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